Systemic antibiotics for treating diabetic foot infections
Anna Selva Olid1, Ivan Solà, Leticia A Barajas-Nava
1Iberoamerican Cochrane Centre, Biomedical Research Institute Sant Pau (IIB-Sant Pau), C. Sant Antoni Maria Claret 167, Pavelló 18 I Planta 0, Barcelona, Spain, 08025.
The Cochrane Database of Systematic Reviews
|September 5, 2015
Summary
Systemic antibiotics are crucial for diabetic foot infections (DFIs), but evidence on the best treatment is limited. While ertapenem showed promise over tigecycline, overall antibiotic effectiveness and safety for DFIs remain unclear due to study limitations.
Area of Science:
- Diabetic foot infections (DFIs) represent a significant clinical challenge, often necessitating systemic antibiotic therapy.
- The selection of appropriate systemic antibiotics for DFIs is critical due to the high risk of non-traumatic amputation in diabetic patients.
Background:
- Diabetic foot infections (DFIs) are the leading cause of non-traumatic amputations in individuals with diabetes.
- Current treatment often involves empirical systemic antibiotic therapy, but optimal drug selection remains uncertain.
Purpose of the Study:
- To evaluate the efficacy and safety of various systemic antibiotics for treating diabetic foot infections (DFIs).
- To compare systemic antibiotics against other treatments, including topical care or placebo, for DFIs.
Main Methods:
- A systematic review and meta-analysis of randomized controlled trials (RCTs) evaluating systemic antibiotics for DFIs.
- Searches were conducted across multiple databases, including Cochrane Wounds Group, MEDLINE, EMBASE, and CINAHL, up to April 2015.
- Primary outcomes included clinical resolution, time to resolution, complications, and adverse effects of antibiotic treatments.
Main Results:
- Twenty trials involving 3791 participants were included, exhibiting significant heterogeneity in design, population, and interventions.
- Ertapenem (with or without vancomycin) demonstrated higher clinical resolution rates compared to tigecycline in one large, low-risk trial.
- Carbapenems showed fewer adverse effects than anti-pseudomonal penicillins, and daptomycin had fewer adverse effects than vancomycin; however, linezolid and tigecycline were associated with more adverse effects in specific comparisons.
Conclusions:
- The evidence comparing systemic antibiotics for DFIs is limited by heterogeneity and high risk of bias, making definitive conclusions difficult.
- While ertapenem showed superiority over tigecycline, the relative efficacy and safety of most other systemic antibiotics for DFIs remain unclear.
- Future research should prioritize blinded outcome assessments, standardized infection severity criteria, clear outcome measures, and defined treatment durations to improve evidence quality.
Related Concept Videos
01:28Acute Pyelonephritis II: Diagnostic Studies and Management
660
Introduction:For diagnosing acute pyelonephritis, a comprehensive patient history is collected to identify symptoms such as dysuria, frequent or urgent urination, flank pain, or costovertebral angle (CVA) tenderness that may suggest a kidney infection.Physical ExaminationDuring the physical examination, CVA tenderness is assessed. This involves gentle percussion over the costovertebral angle, where tenderness often indicates a kidney infection.Diagnostic TestsUrinalysis: Used to identify white...
660
01:30Urinary Tract Infection III: Diagnostic Studies and Interprofessional Care
402
A healthcare provider can diagnose a urinary tract infection (UTI) through several methods:Medical History and Symptoms: The provider will take a detailed medical history and ask about symptoms such as frequent urination, burning sensation during urination, and lower abdominal pain.Urinalysis: A clean-catch urine sample is collected in a sterile container and tested for the presence of bacteria, white blood cells (leukocytes), nitrites, blood, and protein. The presence of leukocytes and...
402
01:27Combined Effects of Drugs: Synergism
7.5K
Synergism is a useful mechanism where combining two or more drugs is more effective than each constituent used alone. Such combinations are also called supra-additive interactions. The drugs collectively enhance the final therapeutic effect by acting on different targets. Another advantage is that the low dose of each constituent drug is sufficient to achieve the desired effect. This helps reduce the duration of therapy and lower the adverse effects of these drugs.
Such synergistic combinations...
Such synergistic combinations...
7.5K
01:15Diabetes: Management and Pharmacotherapy
1.5K
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
1.5K
01:26Oral Hypoglycemic Agents: Biguanides and Glitazones
962
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
962
01:28Pneumonia IV: Management
1.1K
The treatment of pneumonia varies based on its severity and the causative pathogen. Here is a structured approach to managing pneumonia, integrating pharmaceutical and supportive care strategies.
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
Bacterial Pneumonia Treatment
For bacterial pneumonia, antibiotics serve as the cornerstone of therapy. Initial treatment often begins with empirical antibiotics, tailored to the anticipated causative organism and adjusted based on culture results. Key antibiotic choices include:
1.1K